FrançaisAre analysts right about Neurocrine Biosciences (NBIX)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Neurocrine Biosciences, we replayed every analyst price target of the past 12 months and measured the real outcome: 48% were profitable, average return +16% (208 calls). At 3 months: +4% average return (48% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Morgan Stanley | 20 | 30% | +4% |
| HC Wainwright & Co. | 20 | 30% | +8% |
| JP Morgan | 15 | 27% | +0% |
| Canaccord Genuity | 15 | 47% | +11% |
| Oppenheimer | 14 | 50% | +20% |
Valuation
Is Neurocrine Biosciences overvalued, and is it a good time to buy Neurocrine Biosciences right now? If you're wondering, here's a recap to make up your own mind: Neurocrine Biosciences's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price ÷ earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects — but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Neurocrine Biosciences | Sector median (Health Care) |
|---|---|---|
| P/E | 22.9 | 29.4 |
| Forward P/E | 13.0 | 17.1 |
| Net margin | 21% | 12% |
👉 Neurocrine Biosciences trades below its sector median (22.9 vs 29.4) — potentially undervalued, or lower expected growth.
📖 P/E, PEG, margin…: see the glossary
Frequently asked questions
Is Neurocrine Biosciences a buy right now?
The analyst consensus on Neurocrine Biosciences (NBIX) is "Buy" (62 bullish, 0 bearish calls over 12 months). This is not advice: historically, 48% of their targets on this stock turned out profitable over 1 year.
What is Neurocrine Biosciences's price target?
The median 12-month price target is $210 (+35% vs $156), ranging from $170 to $249 (18 analysts).
Are analysts accurate on Neurocrine Biosciences?
Over 1 year, 48% of analyst targets on Neurocrine Biosciences were profitable, for an average return of +16% (across 208 timestamped calls). This is JPI Invest's accuracy metric.
What is the Neurocrine Biosciences stock forecast?
Analysts target a median of $210 within 12 months, i.e. +35% vs the current price. The most bullish targets $249, the most cautious $170.
What is the Neurocrine Biosciences stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $210, +35%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (48%), and the stock's past trajectory.
Is Neurocrine Biosciences overvalued?
Its P/E is 22.9, forward P/E 13.0. A forward P/E lower than the current P/E means earnings are expected to grow.
📊 See the full interactive analysis of Neurocrine Biosciences →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.